BioArctic AB (publ) (LON:0RV2)

Market Cap	2.22B +61.5%
Revenue (ttm)	161.15M +676.8%
Net Income	82.41M
EPS	0.93
Shares Out	n/a
PE Ratio	26.96
Forward PE	123.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,871
Average Volume	26,687
Open	321.80
Previous Close	317.05
Day's Range	314.60 - 322.00
52-Week Range	154.60 - 364.40
Beta	-0.91
RSI	53.16
Earnings Date	May 20, 2026

About BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 131
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RV2

Financial Performance

Financial numbers in SEK